ArticleThoracic cancer2022
miR-223-3p targets FBXW7 to promote epithelial-mesenchymal transition and metastasis in breast cancer.
Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- MicroRNAs in Breast Cancer: Biological Functions and Technologies for Experimental and Therapeutic Applications.Cancers · 2026Review
- Emerging miRNA biomarkers in breast cancer: The role of miR-223, miR-326, and miR-429 in tumor profiling.Molecular biology reports · 2026Article
- Investigating autophagy and miRNAs as therapeutic targets in leukemia.Discover oncology · 2026Review
- MicroRNAs as the critical regulators of ubiquitin-proteasome system through F-box protein targeting during tumor progression.Cancer cell international · 2025Review
- The Association Between miRNA-223-3p Levels and Pain Severity in Fibromyalgia Syndrome: A Molecular Approach.International journal of molecular sciences · 2025Article
- MiR-223-3p Promotes Osteoporosis Progression by Repressing Osteogenic Differentiation via Targeting FHL1/Wnt/β-catenin Signaling.Cell biochemistry and biophysics · 2025Article
- Circular RNA hsa_circ_0002669 is down-regulated byAmerican journal of cancer research · 2025Article
- F-box in breast cancer: mechanism of action and therapeutic potential.American journal of translational research · 2025Review
- The MicroRNA miR-223 Constrains Colitis-associated Tumorigenesis by Limiting Myeloid Cell Infiltration and Chemokine Expression.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Circ_0124346 facilitates cell proliferation of pancreatic adenocarcinoma cells by regulating lipid metabolism via miR-223-3p/ACSL3 axis.Discover oncology · 2024Article
- MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.International journal of molecular sciences · 2024Review
- Transcriptional Up-Regulation of FBXW7 by KInternational journal of molecular sciences · 2024Article
- The impact of ferroptosis and ferroptosis-related non-coding RNAs on breast cancer progression.Frontiers in cell and developmental biology · 2024Review
- FBXW7 in breast cancer: mechanism of action and therapeutic potential.Journal of experimental & clinical cancer research : CR · 2023Review
- Exosomal miRNA-223-3p derived from tumor associated macrophages promotes pulmonary metastasis of breast cancer 4T1 cells.Translational oncology · 2023Article
- Human umbilical cord mesenchymal stromal cell small extracellular vesicle transfer of microRNA-223-3p to lung epithelial cells attenuates inflammation in acute lung injury in mice.Journal of nanobiotechnology · 2023Article
- The intervention effect of Aitongxiao prescription on primary liver cancer rats was evaluated based on high-throughput miRNA sequencing and bioinformatics analysis.Frontiers in oncology · 2023Article
- FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy.Frontiers in oncology · 2023Review
- miR-223: a key regulator of pulmonary inflammation.Frontiers in medicine · 2023Review
- MicroRNAs: A Link between Mammary Gland Development and Breast Cancer.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most common malignant tumor diagnosed in women. It is the second leading cause of cancer-related death among women in the world. Aberrant expression of microRNAs (miRNAs) have been identified to be involved in the development and progression of breast cancer. The aim of this study was to investigate the function of miR-223-3p in breast cancer progression and metastasis.
methodsqRT-PCR was used to analyze the expression levels of miR-223-3p in breast cancer tissues and cell lines. Wound healing and Matrigel assays were used to examine cell motility and invasiveness. FBXW7 3'-UTR construct and luciferase reporter assays were performed for the target gene.
resultsmiR-223-3p was overexpressed in breast cancer tissue and cell lines. A high level of miR-223-3p was associated with poor prognosis in breast cancer patients. In addition, overexpressed miR-223-3p promoted the migration and invasion of breast cancer cells in vitro and in vivo. Mechanistically, we found that tumor suppressor gene FBXW7 is a target of miR-223-3p. Luciferase activity reporter assay indicated miR-223-3p could directly bind with the 3'-UTR of FBXW7. miR-223-3p exhibited its oncogenic role partly by decreasing FBXW7 expression, and consequently promoted the invasion and metastasis of breast cancer cells.
conclusionsOur study revealed a physical and functional relationship among miR-223-3p and FBXW7. By negatively regulating FBXW7 expression, miR-223-3p exerts a tumor promotion role promoting cell invasion and metastasis in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.